Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 70518-1897

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 500mg 70518 1897 01

Divalproex Sodium is a medication in the form of Extended-Release 500mg tablets. The package quantity is 100 HD2. The medication is meant for “RX ONLY”. The NDC code for the medication is 70518-1897-01. LOT #: and expiry date fields are left blank. The medication has been sourced from NDC 65862-0595-01 and manufactured by Aurcbindo Pharma, Dayton, NJ 08810. The package has a direction for use enclosed. It should be stored at a temperature range between 20-26°C (63-77°F), with excursions allowed to 15-30°C (59-86°F) [See USP]. The medication has been repackaged by Remedy Repack.*

FDA Label Image

Divalproex Sodium 500mg 70518 1897 02

Divalproex sodium is a medication available in tablet form with 500mg extended release formula. The package contains 1 HD2 tablet, and it is an RX only medication. The NDC number is 70518-1897-02, and the MFG is Aurcbindo Pharma located in Dayton, NJ. The package insert should be referred to for dosage information. The medication should be stored between 20-26°C, and should be kept out of reach of children. The medication is repackaged by RemedyRepack Inc. in Indiana.*

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium is an extended-release tablet of 500 mg. It comes in a quantity of 30 HD2 and needs a prescription to purchase. The package contains directions for use, and it's important to keep the medicine out of reach of children. Store it at 20-26°C (63-77°F), and it is permissible to keep it at 15-30°C (59-86°F) as per USP. The medicine is repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.466.8762. The Lot number, expiration date, and source NDC are not available in the text.*

FDA Label Image

Figure 1 (Divalproex Fig1)

The text describes a graph, labeled as Figure 1, that compares the reduction in CPS rate of patients taking delayed-release tablets of Divalproex Sodium versus those taking a placebo. The graph shows the percentage of patients who have experienced an improvement, no change, or worsening in their condition. The text is not sufficient to provide further details.*

FDA Label Image

Figure 2 (Divalproex Fig2)

The text describes a figure labeled "Figure 2" which shows the % reduction in CPS rate for high and low dose Divalproex Sodium Delayed-Release Tablets. It includes three categories: improvement, no change, and worsening. The figure shows that the high dose has a greater reduction in CPS rate compared to the low dose.*

FDA Label Image

Figure-3 (Divalproex Fig3)

This appears to be a list of numerical values and some text referring to a medication called Divalproex Sodium Extended-Release Tablets. There is no clear context or further information provided.*

FDA Label Image

Structure (Divalproex Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.